GC502 / AstraZeneca - LARVOL DELTA

Gracell Biotechnologies Acquisition Completed (GlobeNewswire) - "Gracell Biotechnologies Inc...today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the 'Merger Agreement'), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ('Parent'), and Grey Wolf Merger Sub ('Merger Sub'), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent....The Company also announced today that it has requested that trading of the ADSs on the Nasdaq Global Select Market ('Nasdaq') be suspended as of February 22, 2024 (New York Time)."

M&A • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • Lupus • Multiple Myeloma • Oncology • Solid Tumor • Systemic Lupus Erythematosus

EARLY RESULTS OF A SAFETY AND EFFICACY STUDY OF ALLOGENEIC TRUUCAR™ GC502 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) (EHA 2022) - P1 | "CRS in all pts was manageable and resolved after treatment with Ruxolitinib, SOC and supportive care. Robust CAR-T cell expansion was observed in DL2 at 1.5x10 7 cells/kg in heavily pretreated r/r B-ALL patients, including those previously treated with CD19 or CD19-CD22 CAR-T therapies. The study is ongoing and continues accruing patients."

Clinical • Acute Lymphocytic Leukemia • Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Graft versus Host Disease • Hematological Malignancies • Immunology • Neutropenia • Thrombocytopenia • CD19 • CD22 • CD7

Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) (AACR 2022) - "CRS in all pts was manageable and resolved after treatment with Ruxolitinib, SOC and supportive care. TruUCAR™ GC502 demonstrated promising early results with a manageable safety profile. Robust CAR-T cell expansion was observed in DL2 at 1.5x107cells/kg in heavily pretreated r/r B-ALL patients, including those previously treated with CD19 CAR-T therapies. The study is ongoing and continues accruing patients."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD19 • CD22 • CD7

Gracell Biotechnologies Schedules Clinical Update Call After EHA 2022 (PRNewswire) - "Updated clinical data from a multicenter IIT evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in oral abstract presentations on June 5 at ASCO 2022 and on June 12 at EHA 2022; Initial clinical data from an ongoing IIT evaluating GC012F for the treatment of relapsed/refractory B-NHL in a poster presentation on June 10 at EHA 2022; Updated data with longer follow-up of GC502 in relapsed/refractory B-ALL in a poster presentation on June 10 at EHA 2022."

Clinical data • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Gracell Biotechnologies Schedules Clinical Update Call After EHA2022 (PRNewswire) - "Gracell Biotechnologies...announced that the Company plans to hold a clinical update call on June 13 after the European Hematology Association 2022 Hybrid Congress (EHA 2022)....The management team intends to highlight clinical data from three investigator-initiated trials (IIT) for its BCMA/CD19 dual-targeting FasTCAR-T candidate GC012F and allogeneic TruUCAR-T candidate GC502 that will be presented at...ASCO 2022 Annual Meeting and EHA 2022 as follows: Updated clinical data from a multicenter IIT evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in oral abstract presentations on June 5 at ASCO 2022 and on June 12 at EHA 2022; Initial clinical data from an ongoing IIT evaluating GC012F for the treatment of relapsed/refractory B-NHL in a poster presentation on June 10 at EHA 2022; Updated data with longer follow-up of GC502 in relapsed/refractory B-ALL in a poster presentation on June 10 at EHA 2022."

Clinical data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress (PRNewswire) - "Gracell Biotechnologies...announced the details of three abstracts that it will present at the European Hematology Association 2022 Hybrid Congress (EHA2022 Congress), being held from June 9 - June 12 in Vienna, Austria. The abstracts highlight the clinical data from ongoing investigator-initiated trials (IITs) of BCMA/CD19 dual-targeting FasTCAR candidate GC012F in two indications of B-cell non-hodgkin's lymphoma (B-NHL) and relapsed/refractory multiple myeloma (RRMM), and allogeneic TruUCAR candidate GC502 in B-cell acute lymphoblastic leukemia (B-ALL)."

P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Gracell Biotechnologies to Present Data at AACR Annual Meeting 2022 Showcasing Early First-in-Human Results for GC502 in r/r B-ALL (PRNewswire) - P1 | N=15 | NCT05105867 | "Gracell Biotechnologies...announced the early results of a first-in-human clinical study of GC502, an allogeneic CD19/CD7 dual-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)....As highlighted in the AACR poster, three out of four patients achieved minimal residual disease negative complete response or complete response with incomplete count recovery (MRD- CR/CRi), and one patient achieved a partial response at month one and subsequently received allogeneic hematopoietic stem-cell transplantation (allo-HSCT) on day 39."

P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire) - "GC012F: Plan to submit the U.S. IND filing for RRMM in the second half of 2022 and the revised timeline is due to manufacturing capacity constraints at the CDMO. Expect to submit the China IND filing for RRMM in 2022. GC502: First-in-human data from China IIT study in B-cell acute lymphoblastic leukemia (B-ALL) patients will be presented at AACR on April 12, 2022."

IND • Acute Lymphocytic Leukemia • Hematological Malignancies • Multiple Myeloma • Oncology

Gracell Biotechnologies Announces Details of Poster Presentation at AACR Annual Meeting 2022 (PRNewswire) - "Gracell Biotechnologies Inc...announced the details of its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held from April 8-13 in New Orleans, Louisiana....Gracell will present early clinical results of a first-in-human investigator-initiated trial (IIT) on GC502, an allogeneic CD19/CD7 dual-directed CAR-T cell therapy currently under development for multiple B-cell malignancy indications including B-cell acute lymphoblastic leukemia (B-ALL)."

P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

Gracell Biotechnologies Announces Multiple Advancements of TruUCAR Allogeneic CAR-T Platform (PRNewswire) - "Gracell Biotechnologies...announced multiple advancements of its TruUCAR platform, the Company's proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered 'off-the-shelf' as stand-alone therapy at lower cost and with greater convenience....An abstract providing early results of a first-in-human clinical study on GC502 in r/r B-ALL patients has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022....'In addition, enrollment on the IIT for GC027 in patients with T-ALL will be concluded to summarize the clinical findings'."

Clinical data • Enrollment status • P1 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies (ASH 2021) - "It demonstrated robust anti-tumor efficacy and promising potentials to suppress HvG. This report presents an example that the dual CAR design of GC502 may serve as a novel “off-the-shelf” CAR-T technology."

CAR T-Cell Therapy • IO biomarker • Preclinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • CD19 • CD7 • IFNG • IL2 • TNFA

Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy (GC502) for B-Cell Malignancies at the 63rd ASH Annual Meeting (PRNewswire) - "Gracell Biotechnologies Inc...announced preclinical data for GC502, an allogeneic chimeric antigen receptor (CAR) T cell therapy for the treatment of B-cell malignancies, will be presented as a virtual poster at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition as part of the 'Cellular Immunotherapies: Basic and Translational' session on December 11, 2021 from 5:30 p.m.-7:30 p.m.(EST)."

Preclinical • Hematological Malignancies • Oncology